PDE4 ligand 2 is a CRBN E3 ligase ligand. PDE4 ligand 2 can be used to synthesize PROTAC such as PDE4 degrader-1. PDE4 ligand 2 can be studied in research for autoimmune and anti-inflammatory diseases.

KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC50 = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia.

4-[(1E)-2-Nitroethenyl]benzoic acid is an E3 ligase ligand. 4-[(1E)-2-Nitroethenyl]benzoic acid can be used for synthesis of PROTAC BRD4 Degrader-38.

VUF26034 (Compound 12b) is a photoresponsive ligand for the human β2-adrenergic receptor (β2-AR.

MC-02479 is a novel cephalosporin. RWJ-54428 has good activity against most of the organisms tested, including methicillin-resistant staphylococci, E. faecalis, and penicillin-resistant pneumococci, and has moderate activity against E. faecium.

CGP 31608 is a semisynthetic penem derivative with antibacterial activity. CGP 31608 is resistant to many important beta-lactamases (including the mutationally derepressed chromosomal enzymes). CGP 31608 can be used for the research of infection.

S-1255 is an orally active and highly selective endothelin ETA receptor antagonist (Kd=0.39 nM). S-1255 blocks vasoconstriction and sustains hypotensive effects in hypertensive rats. S-1255 is promising for research of hypertension and cardiovascular disorders.

BC-1175 (CB-181963) is a novel cephalosporin and antibacterial agent. CB-181963 displays strong binding to altered PBP 2a. CB-181963 demonstrates marked efficacy against MRSA, Klebsiella pneumoniae, Streptococcus pneumoniae, and Escherichia coli.

BAYV-3522 is an orally effective cephalosporin. BAYV-3522 has antibacterial activity against Gram positive bacteria and some respiratory pathogens. BAYV-3522 can be used in the research of infectious conditions.

HMRZ-62 is an antibacterial agent. HMRZ-62 exhibits antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus faecalis (VRE).

TGI-15 is a highly selective prostaglandin F receptor antagonist. TGI-15 inhibits downstream signaling pathways by blocking the binding of PGF2 α to FP receptors. TGI-15 can be used for research on fibrotic and inflammatory conditions.

BMT-136088 is a radioligand used for positron emission tomography (PET) imaging of idiopathic pulmonary fibrosis.

Sebrinoflast (Compound 5) is a NLRP3 inhibitor with an IC50 ≤1  μM for hNLRP3. Sebrinoflast can be used for inflammatory and cardiovascular diseases including NASH and atherosclerosis and neurological diseases like Alzheimer's disease research.

L-731128 is a novel alkyl citrate. L-731128 can be isolated as a minor component of Sporormiella intermedia (MF 5447, ATCC 20985) fermentations. L-731128 is a potent squalene synthase inhibitor, with an IC50 value of 767 nM.

Hepoxilin A3 methyl ester is the ester form of HxA3. Hepoxilin A3 methyl ester causes a receptor-induced rise in intracellular calcium through the release from intracellular stores in suspended human neutrophils.

AMG 7905 TFA is a hypothermia-inducing transient receptor potential vanilloid type 1 (TRPV1) antagonist. AMG 7905 TFA potentiates TRPV1 channels activation by protons and drives the reflectory inhibition of thermogenesis and tail-skin vasoconstriction, while potently blocking channel activation by capsaicin.

Psa-AR is a PROTAC degrader targeting PSMA. Psa-AR exhibits potent degradation ability of AR, AR-V7, and HSP90, and induces cell apoptosis. Psa-AR can be used for cancer research.

CGP 57698 is an efficient CysLT receptor (Ki = 5.7 nM) antagonist. CGP 57698 can effectively counteract bronchoconstriction caused by LTD4. CGP 57698 can be used for research on asthma or allergic conditions.

Butanixin (2-[(4-Butylphenyl)amino]-3-pyridinecarboxylic acid) is a cyclooxygenase (COX) inhibitor. It exerts anti-inflammatory and analgesic activity by reducing prostaglandin production. It is used in the research of musculoskeletal disorders.

idoBR1 is an orally active amino acid with an amino sugar. idoBR1 can significantly inhibit LPS induced TNF-α production and MAPK signaling pathway. idoBR1 can inhibit bacteria and human sialidase. idoBR1 can inhibit bacterial and human sialidase and reduce the binding of CD44 to hyaluronic acid (HA). idoBR1 can reduce the release of pro-inflammatory factors and promote the generation of anti-inflammatory factors. idoBR1 can be used for research on inflammatory conditions.

Gemigliptin (LC15-0444 ) tartrate hydrate is a selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate hydrate exhibits potent anti-glycation properties. Gemigliptin tartrate hydrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications.

GPI-3000 is a NMDA receptor antagonist. GPI-3000 can ameliorate metabolic injury and shows neuroprotective effect. GPI-3000 can be used for the researches of metabolic and neurological disease.

Boc-VC-PAB-MMAF is a linker that can be synthesized to antibody-drug conjugate (ADC). Boc-VC-PAB-MMAF can be used for the study of cancer.

BIIB042 is a potent, orally active, brain-penetrant, and selective γ-secretase modulator (GSM). BIIB042 reduces Aβ42 and increases Aβ38 levels in cells. BIIB042 significantly reduces brain Aβ42 levels in CF-1 mice and Fischer rats, as well as plasma Aβ42 levels in cynomolgus monkeys. BIIB042 reduces Aβ42 levels and Aβ plaque burden in Tg2576 mice. BIIB042 can be used for alzheimer's disease (AD) research[1][2].

RG-239 is an orally active TGR5 agonist with an EC50 of 120 nM, significantly outperforming Betulinic acid (EC50 = 1.04 μM). RG-239 demonstrates higher selectivity for TGR5 compared to the FXRα. RG-239 increases mitochondrial activity in adipocytes and promotes neurite outgrowth at higher concentrations. RG-239 inhibits LPS-induced iNOS expression and nitrite production in Raw264.7 and microglia cells. RG-239 can be used for the study of type 2 diabetes.

LY459477 is a potent, selective and orally active metabotropic glutamate 2/3 receptor (mGluR2/3) agonist. LY459477 can effectively suppress Phencyclidine-evoked locomotor activity at doses that do not impair neuromuscular coordination. LY459477 can be used for the research of neurological disease.

GW 273629 is a selective nitric oxide synthase inhibitor. GW 273629 exhibits anti-inflammation effect.

(S)-CPW 399 is a subtype-selective full agonist of AMPA receptors, with a 20-fold higher selectivity for GluA1 and GluA2 subunits over GluA3 and GluA4 subunits. (S)-CPW 399 can significantly increase the spontaneous firing rate (FR) of LC noradrenergic neurons by activating AMPA receptors containing GluA1 subunits. (S)-CPW 399 can be used for the study of neurological diseases.

TAN 950A is antifungal amino acid antibiotic. TAN 950A has affinity for three excitatory amino acid (EAA) receptor and can inhibit [3H]AMPA, [3H]kainite and [3H]CPP binding competitively. TAN 950A can be used for the researches of infection and neurological disease.

Ovothiol A disulfide is an inhibitor of light-triggered CF1 ATPase activity.